CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Brain Research Bulletin

• Publication date

  2008-05-15

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.brainresbull.2008.01.010PMID 18395614
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

  2006influential reference
• Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

  2006cited by this paper
• Tau pathology in Alzheimer disease and other tauopathies.

  2005cited by this paper
• Cerebrospinal fluid TAU protein and amyloid β42 in mild cognitive impairment: prediction of progression to Alzheimer’s disease and correlation with the neuropsychological examination

  2005cited by this paper
• Diagnostic Value of FDG-PET and HMPAO-SPET in Patients with Mild Dementia and Mild Cognitive Impairment: Metabolic Index and Perfusion Index

  2005cited by this paper
• Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease.

  2005cited by this paper
• Association between Cognitive Performance and Cortical Glucose Metabolism in Patients with Mild Alzheimer’s Disease

  2005cited by this paper
• Hyperphosphorylated tau protein in the cerebrospinal fluid of patients with Alzheimer's disease and other dementias: preliminary findings.

  2004cited by this paper
• Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

  2004cited by this paper
• Core biological marker candidates of Alzheimer’s disease – perspectives for diagnosis, prediction of outcome and reflection of biological activity

  2004cited by this paper
• Contrasting metabolic impairment in frontotemporal degeneration and early onset Alzheimer's disease

  2004cited by this paper
• MCI conversion to dementia and the APOE genotype

  2004cited by this paper
• [18F]FDG-PET in Patients with Alzheimer’s Disease: Marker of Disease Spread

  2004cited by this paper
• Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study

  2003cited by this paper
• Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

  2003cited by this paper
• PET studies in dementia

  2003cited by this paper
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cited by this paper
• Cerebrospinal fluid levels of total‐tau, phospho‐tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

  2003cited by this paper
• Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

  2003cited by this paper
• The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration.

  2002cited by this paper
• CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease

  2001cited by this paper
• Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development.

  2001cited by this paper
• Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.

  2001cited by this paper
• CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

  2000cited by this paper
• Cerebrospinal fluid levels of Aβ42 and tau: potential markers of Alzheimer’s disease

  1998cited by this paper
• Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.

  1998cited by this paper
• Tau as a marker for Alzheimer's disease.

  1993cited by this paper
• Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type.

  1990cited by this paper
• Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.

  1986cited by this paper
• One of the antigenic determinants of paired helical filaments is related to tau protein.

  1986cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper

• Metabolic dysregulation in cerebral small vessel disease: pathogenesis and therapeutic targets.

  2026cites this paper
• Mechanisms of Cognitive Aging: Health and Pathology

  2026cites this paper
• Cross-Modality Image Translation From Brain 18F-FDG PET/CT Images to Fluid-Attenuated Inversion Recovery Images Using the CypixGAN Framework

  2024cites this paper
• Regional brain metabolism across the Alzheimer's Disease continuum in Down Syndrome

  2024cites this paper
• Multi-modal cross-attention network for Alzheimer's disease diagnosis with multi-modality data

  2023cites this paper
• The potential roles of excitatory-inhibitory imbalances and the repressor element-1 silencing transcription factor in aging and aging-associated diseases.

  2021cites this paper
• Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease

  2019cites this paper
• Unraveling Alzheimer’s Disease Using Drosophila

  2019cites this paper
• Contribution of astrocytes to metabolic dysfunction in the Alzheimer’s disease brain

  2019cites this paper
• Activation of the Brain to Postpone Dementia: A Concept Originating from Postmortem Human Brain Studies

  2019cites this paper
• Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States.

  2018cites this paper
• Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.

  2018cites this paper
• Concordance between brain 18F-FDG PET and cerebrospinal fluid biomarkers in diagnosing Alzheimer's disease.

  2018cites this paper
• Dynamics of proteinopathies in Alzheimer’s disease as measured by PET and CSF biomarkers

  2018cites this paper
• Imaging Biomarkers of Neurodegeneration in Alzheimer’s Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism

  2018cites this paper
• Concordancia entre la PET cerebral con 18F-FDG y los biomarcadores en líquido cefalorraquídeo en el diagnóstico de enfermedad de Alzheimer

  2018cites this paper
• Tau imaging in dementia 1 in vivo tau PET imaging in dementia : pathophysiology , radiotracer quantification , and a systematic review of clinical findings

  2017cites this paper
• Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease

  2017cites this paper
• Imaging Biomarkers in Alzheimer’s Disease: A Practical Guide for Clinicians

  2017cites this paper
• Tau PET and tauopathies

  2016cites this paper
• What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?

  2016cites this paper
• CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson’s Disease—A Preliminary Report

  2016cites this paper
• Functional correlates of t-Tau, p-Tau and A&bgr;1–42 amyloid cerebrospinal fluid levels in Alzheimer’s disease: a 18F-FDG PET/CT study

  2015cites this paper
• Increase in Alzheimer's related markers preceeds memory disturbances: studies in vasopressin-deficient Brattleboro rat.

  2014cites this paper
• 14 Brain Energy Metabolism in Health and Disease

  2014cites this paper
• Neuroimaging in dementia.

  2014cites this paper
• Biomarqueurs du liquide cérébrospinal dans la maladie d’Alzheimer

  2013cites this paper
• Alzheimer CSF biomarkers in routine clinical setting

  2012cites this paper
• Brain Energy Metabolism in Health and Disease

  2012cites this paper
• Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients.

  2012cites this paper
• Systematic review of the diagnostic utility of SPECT imaging in dementia

  2012cites this paper
• Biomarkers in Alzheimer's disease drug development

  2011cites this paper
• Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in Parkinsonian patients

  2011cites this paper
• PET/CT in diagnosis of dementia

  2011cites this paper
• Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment and Dementia

  2010cites this paper
• Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease

  2010cites this paper
• Deep Brain Stimulation of Pedunculopontine Tegmental Nucleus (PPTg) Promotes Cognitive and Metabolic Changes: A Target-Specific Effect or Response to a Low-Frequency Pattern of Stimulation?

  2010cites this paper
• Multiple Defects in Energy Metabolism in Alzheimers Disease

  2010cites this paper
• Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: focus on sleep and cognitive domains.

  2010cites this paper
• Multiple defects in energy metabolism in Alzheimer's disease.

  2010cites this paper
• Cerebrospinal Fluid Tau Protein Levels and 18F-Fluorodeoxyglucose Positron Emission Tomography in the Differential Diagnosis of Alzheimer’s Disease

  2010cites this paper
• Relationships between biomarkers in aging and dementia

  2009cites this paper
• Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

  2009cites this paper
• Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer’s disease

  2009influential citation
• Brain Metabolic Correlates of Cerebrospinal Fluid Beta-Amyloid 42 and Tau in Alzheimer’s Disease

  2009cites this paper
• Tau and tauopathies.

  2007cites this paper
• Computers in Biology and Medicine

  year unknowncites this paper